Summary

Antibody Drug Conjugate Market Growth & Trends

The global antibody drug conjugate market size is expected to reach USD 23.9 billion by 2028, according to a new report by Grand View Research Inc. The market is expected to grow at a CAGR of 23.7% from 2021 to 2028. Increasing investment in R&D and advancements in linker technology are expected to boost the growth of the antibody drug conjugates (ADCs) market.

Antibody-drug conjugates are a novel category of drugs composed of an antibody linked to a cytotoxic drug with a linker. Conventional chemotherapy is intended to kill fast-growing tumor cells. However, it can also damage healthy proliferating cells, which may produce undesirable effects. In contrast, ADCs are designed to increase the efficacy of treatment and decrease the systemic toxicity of chemotherapy drugs. Major players are entering into partnerships for the development & commercialization of these products. For instance, in July 2020, AstraZeneca collaborated with Daiichi Sankyo to develop and commercialize its new ADC candidate, DS-1062, which is in phase 1 trials for triple-negative breast cancer and Non-Small Cell Lung Cancer (NSCLC).

One of the major factors responsible for the growth of the ADCs market is the rising incidence and prevalence of cancer coupled with the growing geriatric population. According to the Cancer Research U.K., during 2015-2017, on average, nearly 36% of new cases were reported among people aged 75 years & above, each year. It is further estimated that by 2035, almost 46% of all cancer cases will be among people in the age group of 75 years & above. Moreover, the rise in the prevalence of cancer in emerging countries further boosts growth. According to Globocan, in 2020, approximately 49.2% of global cancer cases were registered in Asia. Thus, this region remains a major untapped market for ADCs.

ADCs manufacturing is a complicated and expensive process, which requires high capital investment and trained operators, stringent GMP, and high operational difficulties. Challenges in downstream processing of ADCs might restrict the market growth. These include handling MAb-linker-drug binding chemistries, balancing & combining optimal MAb specificity, preventing premature toxin release, and controlling the release of intracellular toxin. Furthermore, the lack of availability of reimbursement policies in developing economies is expected to restrict market growth.

Mergers and acquisitions are one of the key strategies employed by key players to increase their market share. For instance, in December 2020, Boehringer Ingelheim acquired NBE-Therapeutics for USD 1.44 billion. NBE-Therapeutics’ expertise in proprietary platforms for ADC development is expected to help Boehringer Ingelheim in the development of ADC drugs.

Antibody Drug Conjugate Market Report Highlights

• Breast cancer was the largest revenue-generating segment in 2020 due to a high number of approved ADC products, approval of Kadcyla for early-stage breast cancer, and a high target patient population

• The cleavable linker segment dominated the market in 2020 due to its wide adoption in ADC’s product development

• Most of the pipeline and commercially available ADCs are based on cleavable linker technology

• Asia Pacific is expected to witness the fastest CAGR over the forecast period

• This growth can be credited to the increasing investments in R&D by local players and the rising geriatric population in the region

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Industry Outlook
3.1 Market Variable Analysis
3.2 Driver Impact Analysis
3.2.1 Presence of Strong Product Pipeline
3.2.2 Growing Geriatric Population Base
3.2.3 Increasing Incidence and Prevalence of Cancer
3.3 Market Restraint Analysis
3.3.1 High Manufacturing Cost of Antibody-Drug Conjugates and Challenges in Downstream Processing Of ADCs
3.3.2 Stringent Reimbursement Policies for ADCs
3.4 Penetration and Growth Prospect Mapping
3.5 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.6 Porter’s Five Forces Analysis
Chapter 4 Application Business Analysis
4.1 Antibody-Drug Conjugates Market: Application Movement Analysis
4.2 Blood Cancer
4.2.1 Blood Cancer Market Estimates And Forecast, 2017 - 2028
4.2.2 Leukemia
4.2.2.1 Leukemia Market Estimates And Forecast, 2017 - 2028
4.2.3 Multiple Myeloma
4.2.3.1 Multiple Myeloma Market Estimates And Forecast, 2017 - 2028
4.2.4 Lymphoma
4.2.4.1 Lymphoma Market Estimates And Forecast, 2017 - 2028
4.3 Breast Cancer
4.3.1 Breast Cancer Market Estimates And Forecast, 2017 - 2028
4.4 Urothelial Cancer & Bladder Cancer
4.4.1 Urothelial Cancer & Bladder Cancer Market Estimates And Forecast, 2017 - 2028
4.5 Others
4.5.1 Others Market Estimates And Forecast, 2017 - 2028
Chapter 5 Technology Business Analysis
5.1 Antibody-Drug Conjugates Market: Technology Movement Analysis
5.2 Cleavable Linker
5.2.1 Cleavable Linker Market Estimates And Forecast, 2017 - 2028
5.3 Non-cleavable Linker
5.3.1 Non-Cleavable Linker Market Estimates And Forecast, 2017 - 2028
5.4 Linkerless
5.4.1 Linkerless Market Estimates And Forecast, 2017 - 2028
Chapter 6 Regional Business Analysis
6.1 Antibody-Drug Conjugates Market: Regional Movement Analysis
6.2 North America
6.2.1 North America Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.2.2 The U.S.
6.2.2.1 The U.S. market estimates and forecast, 2017 - 2028 (USD Million)
6.2.3 Canada
6.2.3.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
6.3 Europe
6.3.1 Europe Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.3.2 The U.K.
6.3.2.1 The U.K. market estimates and forecast, 2017 - 2028 (USD Million)
6.3.3 Germany
6.3.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
6.3.4 Italy
6.3.4.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
6.3.5 Spain
6.3.5.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
6.3.6 France
6.3.6.1 France market estimates and forecast, 2017 - 2028 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.3 China
6.4.3.1 China Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.4 India
6.4.4.1 India Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.5 Australia
6.4.5.1 Australia Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5 Latin America
6.5.1 Latin America Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6 Middle East & Africa
6.6.1 Middle-East And Africa Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia Market Estimates And Forecast, 2017 - 2028 (USD Million)
6.6.4 UAE
6.6.4.1 UAE Market Estimates And Forecast, 2017 - 2028 (USD Million)
Chapter 7 Competitive Landscape
7.1 Major deals & strategic alliances analysis
7.1.1 New product launch
7.1.2 Mergers and acquisitions
7.1.3 Expansion
7.1.4 Partnerships
7.2 Vendor Landscape
7.2.1 List Of Key Distributors And Channel Partners
7.2.2 Key Company Market Share Analysis, 2020
7.3 Public Companies
7.3.1 Company Market Position Analysis
7.3.2 Competitive Dashboard Analysis
7.4 Private Companies
7.4.1 List Of Key Emerging Companies/Technology Disruptors/ Innovators
Chapter 8 Company Profiles
8.1 Takeda Pharmaceutical Company Limited
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Astrazeneca
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Gilead Sciences, Inc.
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Astellas Pharma
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Seagen, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Daiichi Sankyo Company, Limited
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 GlaxoSmithKline Plc
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 ADC Therapeutics
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives



List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 North America antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 4 North America antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 5 The U.S. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 6 The U.S. antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 7 Canada antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 8 Canada antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 9 Europe antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 10 Europe antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 11 The U.K. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 12 The U.K. antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 13 Germany antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 14 Germany antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 15 France antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 16 France antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 17 Italy antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 18 Italy antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 19 Spain antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 20 Spain antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 21 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 22 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 23 Japan antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 24 Japan antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 25 China antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 26 China antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 27 India antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 28 India antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 29 Australia antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 30 Australia antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 31 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 32 South Korea antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 33 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 34 Latin America antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 35 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 36 Brazil antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 37 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 38 Mexico antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 39 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 40 Argentina antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 41 MEA antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 42 MEA antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 43 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 44 South Africa antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 45 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 46 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 47 UAE antibody-drug conjugates market estimates and forecasts, by application, 2017 - 2028 (USD Million)
TABLE 48 UAE antibody-drug conjugates market estimates and forecasts, by technology, 2017 - 2028 (USD Million)
TABLE 49 List of key distributors
TABLE 50 List of key emerging companies/technology disruptors/innovators

List of Figures

Fig. 1 Antibody-drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Antibody-drug conjugates market snapshot
Fig. 10 Antibody-drug conjugates market driver impact
Fig. 11 Global population by age group, 2016, 2020, & 2027
Fig. 12 Global cancer cases projection,2020-2030 (Number of newly registered cases)
Fig. 13 Antibody-drug conjugates market restraint impact
Fig. 14 Penetration and growth prospect mapping
Fig. 15 SWOT analysis, by factor (political & legal economic and technological)
Fig. 16 Porter’s five forces analysis
Fig. 17 Antibody-drug conjugates market: Application outlook and key takeaways
Fig. 18 Antibody-drug conjugates market: Application movement analysis
Fig. 19 Blood cancer market estimates and forecasts, 2017 - 2028
Fig. 20 Leukemia market estimates and forecasts, 2017 - 2028
Fig. 21 Multiple Myeloma market estimates and forecasts, 2017 - 2028
Fig. 22 Lymphoma market estimates and forecasts, 2017 - 2028
Fig. 23 Breast cancer market estimates and forecasts, 2017 - 2028
Fig. 24 Urothelial cancer market estimates and forecasts, 2017 - 2028
Fig. 25 Others market estimates and forecasts, 2017 - 2028
Fig. 26 Antibody-drug conjugates market: Technology outlook and key takeaways
Fig. 27 Antibody-drug conjugates market: Technology movement analysis
Fig. 28 Cleavable linker market estimates and forecasts, 2017 - 2028
Fig. 29 Non-cleavable linker market estimates and forecasts, 2017 - 2028
Fig. 30 Linkerless market estimates and forecasts, 2017 - 2028
Fig. 31 Antibody-drug conjugates market: Regional outlook and key takeaways
Fig. 32 Antibody-drug conjugates market: Regional movement analysis
Fig. 33 North America
Fig. 34 North America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 35 The U.S.
Fig. 36 The U.S. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 41 The U.K.
Fig. 42 The U.K. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 43 Germany
Fig. 44 Germany market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 45 Italy
Fig. 46 Italy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 47 Spain
Fig. 48 Spain market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 49 France
Fig. 50 France market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 51 Asia Pacific
Fig. 52 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 53 Japan
Fig. 54 Japan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 55 China
Fig. 56 China market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 57 India
Fig. 58 India market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 59 Australia
Fig. 60 Australia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 61 South Korea
Fig. 62 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 63 Latin America
Fig. 64 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 65 Brazil
Fig. 66 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 67 Mexico
Fig. 68 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 69 Argentina
Fig. 70 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 71 Middle East & Africa
Fig. 72 Middle East and Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 73 South Africa
Fig. 74 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 75 Saudi Arabia
Fig. 76 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 77 UAE
Fig. 78 UAE market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 79 Company market share analysis
Fig. 80 Company market position analysis (Revenue US$ mn)
Fig. 81 Company market position analysis (Profit Margin)
Fig. 82 Competitive dashboard analysis
Fig. 83 Regional Network Map